Momenta Pharmaceuticals reported Monday that in a mid-stage clinical trial, an experimental medicine significantly improved the symptoms of patients with generalized myasthenia gravis, a rare neuromuscular disease.
Called nipocalimab, the Momenta drug works by blocking a molecule in the body called neonatal Fc receptor (FcRn), which can trigger certain types of autoimmune diseases. Generalized myasthenia gravis is a chronic and debilitating condition in which the body’s own antibodies disrupt the communication between nerve endings and muscles.
About the Author Reprints
